PALB2 Mutation

CI-VAR-00002707Explore in graph →CIViC 2759

Curated evidence

Evidence by cancer (7 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–7 of 7 evidence items across 6 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Castration-Resistant Prostate Carcinoma1
PALB2 Mutation	Olaparib	Predictive	A	Supports Sensitivity Response	4	accepted	EID8504 This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC	civic
Malignant Breast Neoplasm2
PALB2 Mutation	(prognostic)	Prognostic	C	Supports Poor Outcome	2	submitted	EID9550 Multi-gene cancer predisposition panel testing of a 44-year-old patient diagnosed with rectal cancer revealed a pathogenic PALB2 c.2509G>T variant. This patient had a family history of breast cancer a… (full text at CIViC) PMID ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Pancreatic Neoplasm1
PALB2 Mutation	Rucaparib	Predictive	B	Supports Sensitivity Response	2	submitted	EID9294 For this single-arm phase II trial patients with locally advanced or metastatic pancreatic cancer (neuroendocrine excluded); and had a confirmed pathogenic or likely pathogenic germline (g) or somatic… (full text at CIViC) PMID 33970687 · Reiss et al., 2021 · Open in CIViC	civic

Malignant Prostate Neoplasm1
PALB2 Mutation	Olaparib	Predictive	B	Supports Sensitivity Response	3	submitted	EID7474 In a phase 2 trial, patients with metastatic castration-resistant prostate cancer harboring DNA damage repair (DDR) gene aberrations were treated with olaparib. In gene testing, samples from tumor tis… (full text at CIViC) Open in CIViC	civic

Pancreatic Adenocarcinoma1
BRCA1 Mutation OR BRCA2 Mutation OR PALB2 Mutation	Rucaparib	Predictive	B	Supports Sensitivity Response	3	submitted	EID11317 In this phase II study, 46 patients were enrolled (42 were evaluable; 27 gBRCA2, seven gBRCA1, six gPALB2, and two sBRCA2) and their chemotherapy was discontinued; patients then received rucaparib 600… (full text at CIViC) PMID 33970687 · Reiss et al., 2021 · Open in CIViC	civic

Pancreatic Ductal Adenocarcinoma1
PALB2 Mutation	Talazoparib	Predictive	C	Supports Sensitivity Response	3	submitted	EID10835 A patient with pancreatic ductal adenocarcinoma (PDAC) and a somatic PALB2 mutation (NM_024675.4: c.3350+1G>T) experienced disease progression after 10 cycles of FOFIRINOX and 2 cycles of gemcitabine.… (full text at CIViC) PMID 36119518 · Kachmazov et al., 2022 · Open in CIViC	civic